Loading...
•
Mar 31, 2023
Taysha Gene Therapies Q1 2023 Earnings Report
Reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.
Key Takeaways
Taysha Gene Therapies reported a net loss of $17.6 million for the first quarter of 2023, which was partially offset by revenue of $4.7 million from Astellas Transactions. The company's cash and cash equivalents were $63.4 million as of March 31, 2023, which is expected to support planned operations into the first quarter of 2024.
Screening completed and dosing scheduled for the first potential subject in the Phase 1/2 REVEAL trial in Rett syndrome.
Dosing of the first adult patient with TSHA-102 is expected in Q2 2023, with initial Phase 1/2 clinical data expected in Q2 2023.
CTA submission to UK MHRA for TSHA-102 in pediatric patients with Rett syndrome expected in mid-2023, and IND application to U.S. FDA anticipated in H2 2023.
A formal FDA meeting request submission to discuss the regulatory path forward for TSHA-120 in GAN expected in Q2 2023, with the meeting anticipated in Q3 2023.
Taysha Gene Therapies
Taysha Gene Therapies
Forward Guidance
Taysha continues to expect that its current cash resources will support planned operating expenses and capital requirements into the first quarter of 2024.